The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Developmental Expression of Human Hepatic CYP2C9 and CYP2C19
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 2×
“…content in the oldest age bracket (>5 mos through 18 yrs; N = 79; median = 5.0 yrs) of 18.0 ± 6.0 pmol/mg microsomal protein is significantly less than the total CYP2C specific content of 60 ± 27 pmol/mg protein (N=60; median age=54.5 yrs) reported by Shimada et al. (1994) (ANOVA, p < 0.001).”
BackgroundMethodInfluentialHuman P450 metabolism of warfarin
Kaminsky, L. S., & Zhang, Z.-Y. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00140-4 · Cited by 798
Clinical relevance of genetic polymorphisms in the human CYP2C subfamily
Goldstein, J. A. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01499.x · Cited by 617
Liver‐enriched transcription factors and hepatocyte differentiation
Cereghini, S. (1996) · The FASEB Journal · doi:10.1096/fasebj.10.2.8641560 · Cited by 510
Molecular genetics of the P-450 superfamily
Gonzalez, F. J. (1990) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(90)90006-n · Cited by 493
The orphan nuclear receptor HNF4α determines PXR- and CAR-mediated xenobiotic induction of CYP3A4
Tirona, R. G., Lee, W., Leake, B. F., Lan, L.-B., Cline, C. B., Lamba, V., Parviz, F., Duncan, S. A., Inoue, Y., Gonzalez, F. J., et al. (2003) · Nature Medicine · doi:10.1038/nm815 · Cited by 440
Induction of bilirubin clearance by the constitutive androstane receptor (CAR)
Huang, W., Zhang, J., Chua, S. S., Qatanani, M., Han, Y., Granata, R., & Moore, D. D. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0630614100 · Cited by 390
The Ontogeny of Human Drug-Metabolizing Enzymes: Phase I Oxidative Enzymes
Hines, R. N., & McCarver, D. G. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.2.355 · Cited by 365
Self-citationEvidence That CYP2C19 is the Major (S)-Mephenytoin 4'-Hydroxylase in Humans
Goldstein, J. A., Faletto, M. B., Romkes-Sparks, M., Sullivan, T., Kitareewan, S., Raucy, J. L., Lasker, J. M., & Ghanayem, B. I. (1994) · Biochemistry · doi:10.1021/bi00173a017 · Cited by 360
Cytochrome P450 and the arachidonate cascade 1
Capdevila, J. H., Falck, J. R., & Estabrook, R. W. (1992) · The FASEB Journal · doi:10.1096/fasebj.6.2.1537463 · Cited by 288
Wrighton, S. A., Stevens, J. C., Becker, G. W., & Vandenbranden, M. (1993) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1993.1506 · Cited by 281
Self-citationTranscriptional Regulation of CYP2C9 Gene
Gerbal-Chaloin, S., Daujat, M., Pascussi, J.-M., Pichard-Garcia, L., Vilarem, M.-J., & Maurel, P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107228200 · Cited by 262
Haining, R. L., Hunter, A. P., Veronese, M. E., Trager, W. F., & Rettie, A. E. (1996) · Archives of Biochemistry and Biophysics · doi:10.1006/abbi.1996.0414 · Cited by 249
Self-citationHuman Hepatic Flavin-Containing Monooxygenases 1 (FMO1) and 3 (FMO3) Developmental Expression
Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E., & Hines, R. N. (2002) · Pediatric Research · doi:10.1203/00006450-200202000-00018 · Cited by 245
Self-citationWei, P., Zhang, J., Dowhan, D. H., Han, Y., & Moore, D. D. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500087 · Cited by 240
Identification of Human Liver Cytochrome P450 Isoforms Mediating Omeprazole Metabolism
ANDERSSON, T., MINERS, J. O., VERONESE, M. E., TASSANEEYAKUL, W., TASSANEEYAKUL, W., MEYER, U. A., & BIRKETT, D. J. (1993) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1993.tb00410.x · Cited by 230
Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450–metabolized drugs
Rogers, J. F., Nafziger, A. N., & Bertino, J. S. (2002) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01363-3 · Cited by 215
Gene structure ofCYP2C8 and extrahepatic distribution of the human CYP2Cs
Klose, T. S., Blaisdell, J. A., & Goldstein, J. A. (1999) · Journal of Biochemical and Molecular Toxicology · Cited by 189
Treluyer, J.-M., Gueret, G., Cheron, G., Sonnier, M., & Cresteil, T. (1997) · Pharmacogenetics · doi:10.1097/00008571-199712000-00002 · Cited by 178
Kidd, R. S., Straughn, A. B., Meyer, M. C., Blaisdell, J., Goldstein, J. A., & Dalton, J. T. (1999) · Pharmacogenetics · doi:10.1097/00008571-199902000-00010 · Cited by 167
Ferguson, S. S., LeCluyse, E. L., Negishi, M., & Goldstein, J. A. (2002) · Molecular Pharmacology · doi:10.1124/mol.62.3.737 · Cited by 158
Roles of Human Hepatic Cytochrome P450s 2C9 and 3A4 in the Metabolic Activation of Diclofenac
Tang, W., Stearns, R. A., Wang, R. W., Chiu, S.-H. L., & Baillie, T. A. (1999) · Chemical Research in Toxicology · doi:10.1021/tx9802217 · Cited by 153
Kamiya, A., Inoue, Y., & Gonzalez, F. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50212 · Cited by 140
Edwards, R. J., Adams, D. A., Watts, P. S., Davies, D. S., & Boobis, A. R. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(98)00033-1 · Cited by 134
The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro
Yaşar, Ü., Eliasson, E., Forslund‐Bergengren, C., Tybring, G., Gadd, M., Sjöqvist, F., & Dahl, M. (2001) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-001-0376-7 · Cited by 115
Leemann, T., Transon, C., Bonnabry, P., & Dayer, P. (1993) · PubMed · Cited by 83
Ibeanu, G. C., & Goldstein, J. A. (1995) · Biochemistry · doi:10.1021/bi00025a008 · Cited by 79
CYP2C19 Participates in Tolbutamide Hydroxylation by Human Liver Microsomes
Wester, M. R., Lasker, J. M., Johnson, E. F., & Raucy, J. L. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15373-1 · Cited by 71
Human Liver CYP2B6-Catalyzed Hydroxylation of RP 73401
Stevens, J. C., White, R. B., Hsu, S. H., et al. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36941-1 · Cited by 45
Self-citationSadeque, A. J. M., Thummel, K. E., & Rettie, A. E. (1993) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(93)90138-h · Cited by 45
Self-citationNagata, T., Takahashi, Y., Ishii, Y., Asai, S., Sugahara, M., Nishida, Y., Murata, A., Chin, M., Shichino, H., Koshinaga, T., et al. (2003) · International Journal of Molecular Medicine · doi:10.3892/ijmm.11.6.713 · Cited by 30
Cited by
Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169
Mechanism-Based Concepts of Size and Maturity in Pharmacokinetics
Anderson, B. J., & Holford, N. H. G. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094708 · Cited by 1,125
Pregnancy-Induced Changes in Pharmacokinetics: A Mechanistic-Based Approach
Anderson, G. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544100-00001 · Cited by 648
Johnson, T. N., Rostami-Hodjegan, A., & Tucker, G. T. (2006) · Clinical Pharmacokinetics · doi:10.2165/00003088-200645090-00005 · Cited by 530
Mechanistic Basis of Using Body Size and Maturation to Predict Clearance in Humans
Anderson, B. J., & Holford, N. H. G. (2009) · Drug Metabolism and Pharmacokinetics · doi:10.2133/dmpk.24.25 · Cited by 494
Metadata
- Authors
- Koukouritaki, S. B., Manro, J. R., Marsh, S. A., Stevens, J. C., Rettie, A. E., McCarver, D. G., & Hines, R. N.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2004-03
- Volume
- 308
- Issue
- 3
- Pages
- 965-974
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2114542242
- Cited by
- 325
- References
- 31
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.